Bone matters: Ga-68 PSMA PET/CT volumetrics predict PSA-PFS and OS in bone-dominant mCRPC patients treated with [¹⁷⁷Lu]Lu-PSMA-617
European Journal of Nuclear Medicine and Molecular Imaging · 2026
DOI: 10.1007/s00259-025-07556-w ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2026. Verfasst von Mehmet Oğuz Kartal und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Elazığ Fethi Sekin City Hospital, Elazığ, Türkiye. m.oguzkartal@gmail.com. Hauptthemen laut MEDLINE: Positron Emission Tomography Computed Tomography, Prostatic Neoplasms, Castration-Resistant, Dipeptides, Heterocyclic Compounds, 1-Ring. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 34 Literaturangaben.
Abstract (Originalsprache)
INTRODUCTION: This study aimed to evaluate the prognostic value of baseline, interim, and change-based (Δ) volumetric parameters derived from PSMA PET/CT imaging in predicting PSA progression-free survival (PSA-PFS) and overall survival (OS) in bone-dominant metastatic castration-resistant prostate cancer (mCRPC) patients treated with [¹⁷⁷Lu]Lu-PSMA-617. METHODS: This retrospective study included 56 bone-dominant mCRPC patients who underwent [⁶⁸Ga]Ga-PSMA PET/CT imaging before and after two cycles of [¹⁷⁷Lu]Lu-PSMA therapy. Quantitative parameters, including SUVmean, PSMA tumor volume (PSMA-TV), and total lesion PSMA activity (TL-PSMA), were extracted using a fixed threshold of SUV ≥ 3. Δ values were calculated as the relative change between baseline and interim scans. Associations with PSA-PFS and OS were analyzed using Cox regression and Kaplan-Meier survival analyses. RESULTS: The presence of new lesions on interim PSMA PET/CT and a reduction of PSMA-TV(Bone) ≤ 10.7% were identified as independent predictors of shorter PSA-PFS (p = 0.022 and p = 0.043, respectively). For OS, an interim PSMA-TV(Bone) > 310.3 mL remained an independent prognostic factor both in the entire cohort (p < 0.001) and in the subgroup without early PSA progression (p = 0.002). While baseline SUVmean values were associated with PSA-PFS, no significant association with OS was observed. CONCLUSION: In bone-dominant mCRPC patients treated with [¹⁷⁷Lu]Lu-PSMA, ΔPSMA-TV(Bone) ≤ 10.7% and the presence of new lesions were independent predictors of PSA-PFS, while interim bone tumor volume was significantly associated with OS. These findings highlight the clinical relevance of bone-specific volumetric parameters, which may serve as a potential alternative to whole-body tumor assessments by providing more practical and targeted prognostic insights in this patient population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, Elazığ Fethi Sekin City Hospital, Elazığ, Türkiye. m.oguzkartal@gmail.com.
- Department of Nuclear Medicine, Elazığ Fethi Sekin City Hospital, Elazığ, Türkiye.
- Department of Nuclear Medicine, Ankara Bilkent City Hospital, Ankara Yıldırım Beyazıt University, Ankara, Türkiye.
- Department of Oncology, Ankara Bilkent City Hospital, Ankara Yıldırım Beyazıt University, Ankara, Türkiye.
ORCID-Profile: Mehmet Oğuz Kartal, Ayşenur Sinem Kartal
Zitieren
APA
Kartal, M. O., Kartal, A. S., Coşkun, N., Şendur, M. A. N., & Özdemir, E. (2026). Bone matters: Ga-68 PSMA PET/CT volumetrics predict PSA-PFS and OS in bone-dominant mCRPC patients treated with [¹⁷⁷Lu]Lu-PSMA-617. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-025-07556-w
Vancouver
Kartal MO, Kartal AS, Coşkun N, Şendur MAN, Özdemir E. Bone matters: Ga-68 PSMA PET/CT volumetrics predict PSA-PFS and OS in bone-dominant mCRPC patients treated with [¹⁷⁷Lu]Lu-PSMA-617. European Journal of Nuclear Medicine and Molecular Imaging. 2026. doi:10.1007/s00259-025-07556-w
BibTeX
@article{Kartal2026,
author = {Kartal, Mehmet Oğuz and Kartal, Ayşenur Sinem and Coşkun, Nazım and Şendur, Mehmet Ali Nahit and Özdemir, Elif},
title = {Bone matters: Ga-68 PSMA PET/CT volumetrics predict PSA-PFS and OS in bone-dominant mCRPC patients treated with [¹⁷⁷Lu]Lu-PSMA-617},
journal = {European Journal of Nuclear Medicine and Molecular Imaging},
year = {2026},
doi = {10.1007/s00259-025-07556-w}
}
EUVIMED